BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35430673)

  • 21. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial.
    Zhou X; Mei C; Zhang J; Lu Y; Lan J; Lin S; Zhang Y; Kuang Y; Ren Y; Ma L; Wei J; Ye L; Xu W; Li K; Lu C; Jin J; Tong H
    Hematol Oncol; 2020 Oct; 38(4):531-540. PubMed ID: 32469434
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of granulocyte colony-stimulating factor and risk of relapse in pediatric patients treated for acute myeloid leukemia according to NOPHO-AML 2004 and DB AML-01.
    Løhmann DJA; Asdahl PH; Abrahamsson J; Ha SY; Jónsson ÓG; Kaspers GJL; Koskenvuo M; Lausen B; De Moerloose B; Palle J; Zeller B; Hasle H
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27701. PubMed ID: 30848067
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Risk of myelodysplastic syndrome and acute myeloid leukemia in congenital neutropenias.
    Freedman MH; Alter BP
    Semin Hematol; 2002 Apr; 39(2):128-33. PubMed ID: 11957196
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Age related risk of myelodysplastic syndrome and acute myeloid leukemia among breast cancer survivors.
    Kaplan HG; Malmgren JA; Li CI; Calip GS
    Breast Cancer Res Treat; 2013 Dec; 142(3):629-36. PubMed ID: 24265034
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of myelodysplastic syndrome/ acute myeloid leukemia evolving from aplastic anemia in children, treated with recombinant human G-CSF.
    Imashuku S; Hibi S; Bessho F; Tsuchida M; Nakahata T; Miyazaki S; Tsukimoto I; Hamajima N;
    Haematologica; 2003 Nov; 88(11):ECR31. PubMed ID: 14607763
    [TBL] [Abstract][Full Text] [Related]  

  • 26. HAG (Homoharringtonine, Cytarabine, G-CSF) Regimen for the Treatment of Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Meta-Analysis with 2,314 Participants.
    Xie M; Jiang Q; Li L; Zhu J; Zhu L; Zhou D; Zheng Y; Yang X; Zhu M; Sun J; Xie W; Ye X
    PLoS One; 2016; 11(10):e0164238. PubMed ID: 27706258
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biosimilar Filgrastim (Tevagrastim, XMO2) for Allogeneic Hematopoietic Stem Cell Mobilization and Transplantation in Patients with Acute Myelogenous Leukemia/Myelodysplastic Syndromes.
    Danylesko I; Sareli R; Bloom-Varda N; Yerushalmi R; Shem-Tov N; Shimoni A; Nagler A
    Biol Blood Marrow Transplant; 2016 Feb; 22(2):277-283. PubMed ID: 26343949
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of acute myeloid leukemia and myelodysplastic syndrome among older women receiving anthracycline-based adjuvant chemotherapy for breast cancer on Modern Cooperative Group Trials (Alliance A151511).
    Freedman RA; Seisler DK; Foster JC; Sloan JA; Lafky JM; Kimmick GG; Hurria A; Cohen HJ; Winer EP; Hudis CA; Partridge AH; Carey LA; Jatoi A; Klepin HD; Citron M; Berry DA; Shulman LN; Buzdar AU; Suman VJ; Muss HB
    Breast Cancer Res Treat; 2017 Jan; 161(2):363-373. PubMed ID: 27866278
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [A clinical trial for homoharringtonine and low-dose cytosine arabinoside combined with G-CSF or GM-CSF to treat the relapsed or refractory acute myeloid leukemia (AML), geriatric AML and advanced myelodysplastic syndromes].
    Xu J; Xu CG; Liu T; Xiang B; Chang H; He C
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Jan; 40(1):129-32. PubMed ID: 19292062
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of acute myeloid leukemia and myelodysplastic syndrome with orally administered cytarabine ocfosfate and granulocyte colony-stimulating factor.
    Okumura H; Yoshida T; Takamatsu H; Katoh T; Murashima M; Watanabe A; Yamauchi H; Matano S; Chuhjo T; Takeshima M; Kaya H; Ohtake S; Nakamura S; Matsuda T
    Int J Hematol; 1997 Apr; 65(3):263-8. PubMed ID: 9114597
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression and functional analysis of granulocyte colony-stimulating factor receptors on CD34++ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukaemia.
    Sultana TA; Harada H; Ito K; Tanaka H; Kyo T; Kimura A
    Br J Haematol; 2003 Apr; 121(1):63-75. PubMed ID: 12670333
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hypoplastic myelodysplastic syndrome progressing to acute myelocytic leukemia (M2) after treatment with G-CSF and immunosuppressants].
    Miyata A; Deguchi S; Kikuchi T; Osada T; Sanada H
    Rinsho Ketsueki; 1998 Jun; 39(6):453-9. PubMed ID: 9695675
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and safety of CHG regimen (low-dose cytarabine, homoharringtonine with G-CSF priming) as induction chemotherapy for elderly patients with high-risk MDS or AML transformed from MDS.
    Wu L; Li X; Su J; He Q; Zhang X; Chang C; Pu Q
    J Cancer Res Clin Oncol; 2011 Oct; 137(10):1563-9. PubMed ID: 21845438
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Granulocyte-colony stimulating factor use and medical costs after initial adjuvant chemotherapy in older patients with early-stage breast cancer.
    Griffiths RI; Barron RL; Gleeson ML; Danese MD; O'Hagan A; Chia VM; Legg JC; Lyman GH
    Pharmacoeconomics; 2012 Feb; 30(2):103-18. PubMed ID: 21967155
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Incidence of secondary myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) in patients with ovarian or breast cancer in a real-world setting in the United States.
    Shenolikar R; Durden E; Meyer N; Lenhart G; Moore K
    Gynecol Oncol; 2018 Nov; 151(2):190-195. PubMed ID: 30268525
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased incidence of myelodysplastic syndrome and acute myeloid leukemia following breast cancer treatment with radiation alone or combined with chemotherapy: a registry cohort analysis 1990-2005.
    Kaplan HG; Malmgren JA; Atwood MK
    BMC Cancer; 2011 Jun; 11():260. PubMed ID: 21693006
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of Granulocyte-Macrophage Colony-Stimulating Factor in Acute Myeloid Leukemia/Myelodysplastic Syndromes.
    Kassem NM; Ayad AM; El Husseiny NM; El-Demerdash DM; Kassem HA; Mattar MM
    J Glob Oncol; 2018 Sep; 4():1-6. PubMed ID: 30241179
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders.
    Kaplan HG; Calip GS; Malmgren JA
    Oncologist; 2020 May; 25(5):391-397. PubMed ID: 32073195
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recombinant human granulocyte-macrophage colony-stimulating factor in combination with standard induction chemotherapy in acute myeloid leukemia evolving from myelodysplastic syndromes: a pilot study.
    Bernell P; Kimby E; Hast R
    Leukemia; 1994 Oct; 8(10):1631-9. PubMed ID: 7934158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.